Loading organizations...

§ Venture Capital · New York City, NY, USA
This VC firm invests in science and tech-based startups with a focus on edtech, biomedical tech, AI, and media tech, empowering growth through defensibility ...
Saltagen Ventures is an early-stage venture capital firm that invests in science and technology-based startups. Its investment strategy focuses on the verticals of edtech, biomedical technology, AI and machine learning, and media technology. They search for startups that have strong defensibility and patentable technology and empowers them to growtheir business and develop efficiencies. The firm was founded in 2017 in Central, Hong Kong by Joseph Fung.
Key people at Saltagen Ventures.
Saltagen Ventures is an early-stage venture capital firm focused on investing in science- and technology-based startups, particularly in deep biotechnology, AI, edtech, biomedical tech, and media tech sectors. Their mission is to empower startups to grow globally by providing capital, mentorship, and strategic resources, with a strong emphasis on building defensible, fundamental technological innovations that can transform industries. The firm operates primarily across North America and Asia, leveraging its strategic presence in Canada and Hong Kong to help startups scale across these markets. Saltagen Ventures plays a significant role in nurturing startups that address complex scientific and technological challenges, thereby contributing to the growth of the global innovation ecosystem[1][4].
Founded with a vision to bridge technology ecosystems between North America and Asia, Saltagen Ventures has evolved into a specialized fund focusing on early-stage deep biotechnology startups and other science-driven ventures. The firm’s leadership includes experienced partners such as Joseph Fung (Managing Partner) and Alan Chen, who bring extensive backgrounds in venture capital and entrepreneurship across the Pacific. Their approach has been shaped by a strategic operator-first mindset, emphasizing early-stage investments with follow-on capital reserved for promising companies. This strategy has enabled Saltagen to build a portfolio of high-growth potential startups, including notable investments like PulseMedica, a life sciences company that raised $12 million in a round led by Saltagen in 2024[1][3][4].
Saltagen Ventures rides the wave of increasing globalization in technology innovation, particularly the convergence of biotech, AI, and deep tech sectors. The timing is critical as scientific breakthroughs and AI advancements accelerate, creating fertile ground for startups with fundamental technological disruptions. Market forces such as growing demand for biomedical innovation, cross-border collaboration, and the rise of Asia as a tech powerhouse work in Saltagen’s favor. By bridging ecosystems in North America and Asia, Saltagen not only facilitates capital flow but also knowledge exchange, helping startups overcome geographic and market-entry barriers. This positions the firm as a key enabler in the global deep tech and biotech startup ecosystem[1][4].
Looking ahead, Saltagen Ventures is poised to deepen its focus on deep biotechnology and AI-driven science startups, leveraging its unique cross-Pacific positioning to capitalize on emerging trends in health tech, edtech, and media tech. As global demand for innovative biotech solutions grows, Saltagen’s influence is likely to expand, potentially driving more cross-border exits and partnerships. The firm’s operator-first, data-driven investment philosophy and strategic follow-on capital approach will continue to shape its portfolio’s growth trajectory. In a rapidly evolving tech landscape, Saltagen Ventures stands out as a catalyst for startups aiming to build globally competitive, defensible technologies, reinforcing its role as a bridge between North American and Asian innovation hubs[1][4].
Key people at Saltagen Ventures.
Saltagen Ventures has more than 26 tracked investments across 22 companies. The latest tracked deal is $11.0M Seed in Reliant AI in August 2024.